John D Lambris Selected Research

Complement C3-C5 Convertases (C3 Convertase)

5/2022	Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research - 20 years of experience and future perspectives.
5/2014	Crosstalk between the coagulation and complement systems in sepsis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John D Lambris Research Topics

Disease

66	Inflammation (Inflammations) 11/2022 - 09/2002
25	Neoplasms (Cancer) 01/2022 - 02/2005
18	Sepsis (Septicemia) 01/2021 - 07/2002
15	Periodontitis 06/2022 - 02/2010
14	Infections 05/2022 - 11/2006
10	COVID-19 01/2022 - 01/2020
10	Macular Degeneration (Age-Related Maculopathy) 12/2020 - 11/2007
8	Thrombosis (Thrombus) 01/2019 - 12/2003
8	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/2018 - 03/2014
7	Thromboinflammation 12/2021 - 01/2013
7	Hemolysis 01/2020 - 03/2014
7	Dysbiosis 01/2019 - 11/2012
6	Periodontal Diseases (Periodontal Disease) 10/2021 - 11/2011
6	Bacterial Infections (Bacterial Infection) 01/2021 - 12/2008
5	Wounds and Injuries (Trauma) 01/2020 - 03/2003
4	Lung Neoplasms (Lung Cancer) 01/2022 - 11/2012
4	Disease Progression 01/2020 - 05/2010
4	Chronic Kidney Failure (Chronic Renal Failure) 01/2019 - 07/2010
4	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2017 - 08/2002
4	Fibrosis (Cirrhosis) 01/2017 - 10/2013
4	Respiratory Hypersensitivity 01/2013 - 03/2004
3	Hemorrhage 12/2021 - 12/2008
3	Thrombocytopenia (Thrombopenia) 11/2021 - 08/2010
3	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 11/2020 - 06/2006
3	Hemorrhagic Shock 01/2020 - 01/2019
3	Edema (Dropsy) 01/2019 - 10/2013
3	Multiple Trauma (Multiple Injuries) 01/2019 - 11/2010
3	Kidney Diseases (Kidney Disease) 01/2019 - 01/2016
3	Carcinogenesis 10/2018 - 10/2016
3	Rare Diseases (Rare Disease) 01/2016 - 09/2007
3	Smallpox (Variola) 06/2015 - 08/2003
3	Asthma (Bronchial Asthma) 01/2013 - 03/2006
3	Hereditary Complement Deficiency Diseases 11/2012 - 09/2007
2	Geographic Atrophy 07/2022 - 01/2020
2	Air Embolism (Gas Embolism) 05/2022 - 12/2021
2	Thrombotic Microangiopathies 11/2020 - 11/2020
2	Pneumonia (Pneumonitis) 01/2020 - 01/2013
2	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 01/2019
2	Multiple Organ Failure (MODS) 01/2019 - 08/2010
2	Membranoproliferative Glomerulonephritis (Membranoproliferative Glomerulonephritis, Type II) 01/2019 - 09/2007
2	Cardiovascular Diseases (Cardiovascular Disease) 10/2018 - 01/2017
2	Chronic Disease (Chronic Diseases) 10/2016 - 01/2013
2	Reperfusion Injury 04/2014 - 12/2009
2	Stroke (Strokes) 04/2014 - 01/2007
2	Atherosclerosis 03/2014 - 02/2010
2	Immune System Diseases (Immune Disorders) 01/2013 - 11/2006
2	Renal Insufficiency (Renal Failure) 11/2012 - 05/2005

Drug/Important Bio-Agent (IBA)

140	Complement System Proteins (Complement)IBA 11/2022 - 08/2002
19	Anaphylatoxin C5a ReceptorIBA 01/2018 - 07/2002
16	compstatinIBA 11/2020 - 10/2006
12	Complement C3 (C3 Complement)IBA 12/2021 - 01/2003
12	Proteins (Proteins, Gene)FDA Link 01/2018 - 03/2003
11	Complement Inactivating AgentsIBA 01/2019 - 10/2004
11	AnaphylatoxinsIBA 10/2018 - 10/2002
10	CytokinesIBA 11/2020 - 01/2003
8	Pharmaceutical PreparationsIBA 10/2021 - 01/2008
8	Peptides (Polypeptides)IBA 03/2016 - 12/2003
7	AntibodiesIBA 11/2021 - 12/2002
7	Interleukin-6 (Interleukin 6)IBA 11/2020 - 01/2003
5	AMY-101IBA 06/2022 - 09/2017
5	Complement C5a (Complement 5a)IBA 01/2022 - 12/2003
5	Biological ProductsIBA 11/2020 - 04/2006
5	eculizumab FDA Link 11/2020 - 09/2007
5	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2017 - 09/2008
4	Antigen-Antibody Complex (Immune Complex)IBA 11/2021 - 06/2006
4	Complement Receptors (Complement Receptor)IBA 01/2021 - 04/2011
4	Biocompatible Materials (Biomaterials)IBA 01/2013 - 01/2007
3	CholesterolIBA 05/2022 - 03/2014
3	ChemokinesIBA 01/2021 - 11/2015
3	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2019 - 10/2014
3	Interleukin-10 (Interleukin 10)IBA 10/2013 - 05/2010
3	Messenger RNA (mRNA)IBA 08/2009 - 07/2002
3	VaccinesIBA 02/2005 - 01/2003
2	Complement C3-C5 Convertases (C3 Convertase)IBA 05/2022 - 05/2014
2	Pathogen-Associated Molecular Pattern MoleculesIBA 05/2022 - 01/2019
2	lepirudin (Refludan)FDA Link 12/2021 - 09/2002
2	AntigensIBA 11/2021 - 04/2006
2	Immunoglobulin G (IgG)IBA 11/2021 - 10/2006
2	InterleukinsIBA 01/2021 - 04/2014
2	Toll-Like Receptor 4IBA 01/2021 - 01/2016
2	Thromboplastin (Tissue Factor)IBA 11/2020 - 06/2008
2	Thrombin FDA Link 11/2020 - 11/2010
2	Monoclonal AntibodiesIBA 11/2020 - 01/2014
2	Retinaldehyde (Retinal)IBA 01/2020 - 07/2015
2	Dichlorodiphenyldichloroethane (DDD)IBA 01/2019 - 09/2007
2	Complement Factor H (Factor H)IBA 01/2019 - 01/2017
2	Glycoproteins (Glycoprotein)IBA 10/2018 - 01/2016
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 08/2010
2	Prostaglandins AIBA 01/2017 - 01/2016
2	CollagenIBA 11/2015 - 02/2014
2	Hemostatics (Antihemorrhagics)IBA 05/2014 - 08/2010
2	Peptide Hydrolases (Proteases)FDA Link 02/2014 - 10/2013
2	Interleukin-8 (Interleukin 8)IBA 01/2013 - 03/2011
2	AllergensIBA 01/2013 - 03/2006
2	Glucose (Dextrose)FDA LinkGeneric 11/2011 - 10/2010

Therapy/Procedure

32	Therapeutics 01/2022 - 01/2003
5	Renal Dialysis (Hemodialysis) 01/2019 - 01/2007
3	Immunotherapy 01/2019 - 01/2014
3	Transplantation 01/2016 - 01/2013
3	Ligation 06/2014 - 07/2002